INmune Bio, Inc.

As of June 20, 2025, the technical trend is mildly bearish, supported by bearish momentum indicators and Bollinger Bands, despite some daily moving averages showing mild bullishness.

INmune Bio, Inc. is a clinical-stage pharmaceutical company focused on developing immunotherapy treatments for cancer. It has a market cap of approximately $159.46 million, with recent net sales of $0 million and a net loss of $10 million.

As of Jun 18, INmune Bio, Inc. has a market capitalization of 159.46 million and reported net sales of 0.05 million with a net profit of -40.80 million over the last four quarters. Shareholder's funds were 32.10 million, and total assets were 39.56 million as of Dec 24.